Enliven Therapeutics Inc. Company Profile
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics at a glance
Enliven Therapeutics Inc. (NASDAQ: ELVN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boulder, CO. Enliven Therapeutics is led by Mr. Richard A. Fair M.B.A. and employs about 67 people. The company's shares have traded publicly since 2020.
At a market capitalization of $2.98 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001672619, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Enliven Therapeutics do?
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Business description based on the company's public filings.
Company information
- Legal name
- Enliven Therapeutics Inc.
- Ticker
- NASDAQ: ELVN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard A. Fair M.B.A.
- Employees
- 67
- Headquarters
- 6200 Lookout Road, Boulder, CO, United States
- Phone
- 720 647 8519
- Website
- enliventherapeutics.com
- IPO year
- 2020
- Market cap
- $2.98B
- SEC CIK
- 0001672619
- Latest annual report
- 10-K · Mar 3, 2026
Companies similar to Enliven Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RCUSArcus Biosciences Inc. | 24.41 | +2.43% | $3.07B | vs ELVN |
| DYNDyne Therapeutics Inc. | 16.64 | +1.65% | $3.11B | vs ELVN |
| ZLABZai Lab Limited ADR | 24.99 | +0.73% | $2.81B | vs ELVN |
| PGENPrecigen Inc. | 7.81 | +2.76% | $2.80B | vs ELVN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.44 | +3.19% | $2.76B | vs ELVN |
| ARQTArcutis Biotherapeutics Inc. | 26.58 | +8.53% | $3.34B | vs ELVN |
| MBXMBX Biosciences Inc. | 53.24 | -0.02% | $2.56B | vs ELVN |
| PBLSParabilis Medicines Inc. | 27.48 | -2.17% | $3.39B | vs ELVN |